Sana, Beam Therapeutics sign $50M CRISPR tech deal


Sana Biotechnology will pay Beam Therapeutics $50 million for non-exclusive commercial rights for its precise gene editing system called CRISPR-Cas12b. Beam is also eligible to receive additional payments for development and sales milestones.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.